AFC
TARS icon

Ares Financial Consulting’s Tarsus Pharmaceuticals TARS Stock Holding History

Ares Financial Consulting’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$818 Buy
+13
New +$831 ﹤0.01% 1034

Other funds holding TARS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Ares Financial Consulting's TARS Position: Q2 2026 in Review

Ares Financial Consulting opened a new position in Tarsus Pharmaceuticals (TARS) in Q2 2026: 13 shares worth $818. The stake represents ﹤0.01% of the portfolio and ranks #1034 among its holdings.

256 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

  • Ares Financial Consulting held 13 shares of Tarsus Pharmaceuticals worth $818 as of Q2 2026.
  • Tarsus Pharmaceuticals was a new Ares Financial Consulting position in Q2 2026.
  • Tarsus Pharmaceuticals made up ﹤0.01% of Ares Financial Consulting's portfolio in Q2 2026, its #1034 holding.
  • 256 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on Ares Financial Consulting's 13F filing for Q2 2026, filed 9 Jul 2026.